Open Access4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion
Author(s) -
Gen Wang,
Sisi Qin,
Jacqueline Zayas,
James N. Ingle,
Mohan Liu,
Richard M. Weinshilboum,
Kunwei Shen,
Liewei Wang
Publication year - 2019
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-019-05194-z
Subject(s) - biology , gene knockdown , cancer research , docetaxel , tamoxifen , breast cancer , estrogen receptor , single nucleotide polymorphism , estrogen receptor alpha , oncology , medicine , genetics , genotype , cancer , gene
In early stage, ERα-positive breast cancer, concurrent use of endocrine therapy and chemotherapy has not been shown to be superior to sequential use. We hypothesized that genetic biomarkers can aid in selecting patients who would benefit from chemo-endocrine therapy. Our previous studies revealed that ZNF423 is a transcription factor for BRCA1 and an intronic single nucleotide polymorphism (SNP) in ZNF423, rs9940645, determines tamoxifen response. Here, we identified mitosis-related genes that are regulated by ZNF423 which led us to investigate taxane response in a rs9940645 SNP- and tamoxifen-dependent fashion.